INTRODUCTION: Despite availability of safe and cost-effective vaccines to prevent it, measles remains one of the significant causes of death among children under five years of age globally. The World Health Organization (WHO) European Region has seen a drastic decline in measles and rubella cases in recent years, and a few of the once common measles genotypes are no longer detected. Buoyed by this success, all Member States of the Region reconfirmed their commitment in 2010 to eliminating measles and rubella, and made this a central objective of the European Vaccine Action Plan 2015-2020 (EVAP). Nevertheless, sporadic outbreaks continue, recently affecting primarily adolescents and young adults with no vaccination or an incomplete vaccination history. The European Regional Verification Commission for Measles and Rubella Elimination was established in 2011 to evaluate the status of measles and rubella elimination based on documentation submitted annually by each country's national verification committee. DISCUSSION: Each country's commitment to eliminate measles and rubella is influenced by competing health priorities, and in some cases lack of capacity and resources. All countries need to improve case-base surveillance for both measles and rubella, ensure documentation of each outbreak and strengthen the link between epidemiology and laboratory data. Achieving high coverage with measles- and rubella-containing vaccines will require a multisectoral approach to address the root causes of lower uptake in identified communities including service delivery challenges or vaccine safety concerns caused by circulating myths about vaccination. CONCLUSIONS: The WHO European Region has made steady progress towards eliminating measles and rubella and over half of the countries interrupted endemic transmission of both diseases by 2015. The programmatic challenges in disease surveillance, vaccination service delivery and communication in the remaining endemic countries should be addressed through periodic evaluation of the strategies by all stakeholders and exploring additional opportunities to accelerate the ongoing elimination activities.
INTRODUCTION: Despite availability of safe and cost-effective vaccines to prevent it, measles remains one of the significant causes of death among children under five years of age globally. The World Health Organization (WHO) European Region has seen a drastic decline in measles and rubella cases in recent years, and a few of the once common measles genotypes are no longer detected. Buoyed by this success, all Member States of the Region reconfirmed their commitment in 2010 to eliminating measles and rubella, and made this a central objective of the European Vaccine Action Plan 2015-2020 (EVAP). Nevertheless, sporadic outbreaks continue, recently affecting primarily adolescents and young adults with no vaccination or an incomplete vaccination history. The European Regional Verification Commission for Measles and Rubella Elimination was established in 2011 to evaluate the status of measles and rubella elimination based on documentation submitted annually by each country's national verification committee. DISCUSSION: Each country's commitment to eliminate measles and rubella is influenced by competing health priorities, and in some cases lack of capacity and resources. All countries need to improve case-base surveillance for both measles and rubella, ensure documentation of each outbreak and strengthen the link between epidemiology and laboratory data. Achieving high coverage with measles- and rubella-containing vaccines will require a multisectoral approach to address the root causes of lower uptake in identified communities including service delivery challenges or vaccine safety concerns caused by circulating myths about vaccination. CONCLUSIONS: The WHO European Region has made steady progress towards eliminating measles and rubella and over half of the countries interrupted endemic transmission of both diseases by 2015. The programmatic challenges in disease surveillance, vaccination service delivery and communication in the remaining endemic countries should be addressed through periodic evaluation of the strategies by all stakeholders and exploring additional opportunities to accelerate the ongoing elimination activities.
Authors: Gavin B Grant; Susan E Reef; Alya Dabbagh; Marta Gacic-Dobo; Peter M Strebel Journal: MMWR Morb Mortal Wkly Rep Date: 2015-09-25 Impact factor: 17.586
Authors: Lara J Wolfson; Rebecca F Grais; Francisco J Luquero; Maureen E Birmingham; Peter M Strebel Journal: Int J Epidemiol Date: 2009-02 Impact factor: 7.196
Authors: Minal K Patel; Marta Gacic-Dobo; Peter M Strebel; Alya Dabbagh; Mick N Mulders; Jean-Marie Okwo-Bele; Laure Dumolard; Paul A Rota; Katrina Kretsinger; James L Goodson Journal: MMWR Morb Mortal Wkly Rep Date: 2016-11-11 Impact factor: 17.586
Authors: Robert E Black; Simon Cousens; Hope L Johnson; Joy E Lawn; Igor Rudan; Diego G Bassani; Prabhat Jha; Harry Campbell; Christa Fischer Walker; Richard Cibulskis; Thomas Eisele; Li Liu; Colin Mathers Journal: Lancet Date: 2010-05-11 Impact factor: 79.321
Authors: Antonietta Filia; Antonino Bella; Martina Del Manso; Melissa Baggieri; Fabio Magurano; Maria Cristina Rota Journal: Euro Surveill Date: 2017-09-14
Authors: Alexandra Jablonka; Christine Happle; Martin Wetzke; Christian Dopfer; Sonja Merkesdal; Reinhold E Schmidt; Georg M N Behrens; Philipp Solbach Journal: Infect Dis Ther Date: 2017-09-05
Authors: Jordan Lee Tustin; Natasha Sarah Crowcroft; Dionne Gesink; Ian Johnson; Jennifer Keelan; Barbara Lachapelle Journal: JMIR Public Health Surveill Date: 2018-09-20